McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.

Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.

Flush with cash, the controlling stakeholder of Novo Nordisk’s life sciences investment arm is increasing its financing of other biopharma innovators.

Jeeva’s founder and CEO talks to Scrip about how the firm’s clinical trial management platform does away with the need for numerous point solutions and vendors, enabling sponsors to undertake trials more effectively including in the complex and competitive oncology space.

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

The German biotech has unveiled a $150m series D financing round to support a “broad Phase IIb development program for visugromab” and explore its potential to induce cancer remission depth and durability across multiple solid tumor indications.

IGBA's secretary general, in an interview with Scrip, bolsters the case for enabling single global development of off-patent medicines and the acceptance of foreign comparators in bioequivalence studies as complex and niche therapeutics increasingly dot pharma’s pipeline. The global off-patent industry association, she maintained, is also “paying attention” to patent quality in various regions.

In a major boost for the UK biotech sector, an impressive sum has been raised by Beacon Therapeutics to support its R&D activities in ophthalmic gene therapies.

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

On the back of a “truly one in a million” case, Ashibio has revived research into Gilead's discontinued asset andecaliximab after it showed promise in the ultra-rare musculoskeletal condition FOP.

Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.

The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.

SK pharmteco CEO Joerg Ahlgrimm talks to Scrip about the "excitement" at BIO, potential CDMO shifts amid the US BIOSECURE Act, and the Korean CDMO's focus on business as usual as it seeks to diversify and grow.

Parexel’s chief strategy officer, clinical EVP and India head share thoughts on a winner’s mindset for artificial intelligence, benefits of a “federated approach” to clinical data sharing, support for reimbursement and a cascading impact of obesity treatments, in a two-part interview with Scrip.

Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.